Meyd-873 _verified_ [FRESH • CHOICE]

| | Information | | :--- | :--- | | Release Date | January 16, 2024 | | Runtime | 150 minutes | | Studio / Label | Madonna / Goro Tameike | | Director | Goro Tameike (溜池ゴロー) | | Actress | Ai Sayama (佐山愛) | | Genre | Drama, Romance, Mature Woman | | Subtitles | English, Chinese, Indonesian, Korean |

As with all Japanese adult video productions, MEYD-873 adheres to domestic content regulations. The required mosaic processing is applied consistently throughout the runtime, maintaining legal compliance while preserving entertainment value. International distribution considers regional laws regarding adult content importation and viewing. MEYD-873

| Phase | Design | Target Population | Primary Endpoint | Expected Milestones | |-------|--------|-------------------|------------------|---------------------| | (dose‑finding, safety) | Open‑label, 3‑plus‑3 escalation → expansion cohorts | KRAS‑G12D+ solid tumors (pancreatic, colorectal, NSCLC) with RAF‑DimerScore ≥ 2 | ORR (RECIST v1.1) + safety | IND filing Q3 2024 → First patient in Q1 2025 | | Phase 2b (confirmatory) | Randomized, double‑blind, MEYD‑873 + standard chemo vs. chemo alone | Same as above | PFS, OS, and biomarker‑driven subgroup analysis | Topline data Q4 2026 | | Phase 3 (global pivotal) | Multi‑regional, double‑blind | KRAS‑G12D+/RAF‑high metastatic pancreatic adenocarcinoma (primary) and KRAS‑G12D+ NSCLC (secondary) | OS superiority | NDA submission Q2 2029 | | | Information | | :--- | :---

This is the main event. Honma specializes in playing refined, elegant women with hidden fires. Her micro-expressions—the slight lip bite, the averted eyes, the trembling hands—sell the “I shouldn’t want this, but I desperately do” conflict perfectly. | Phase | Design | Target Population |

Digital distribution options provide immediate access for consumers in permitted regions, while physical media remains available through secondary markets as the release ages. Pricing varies significantly between new and used copies, with mint condition original packaging commanding premium rates among collectors.

| Indication | Rationale | Proposed Delivery | |------------|-----------|--------------------| | | Direct modulation of peripheral Nav1.7 reduces ectopic firing without systemic analgesics | Subcutaneous infusion pump + percutaneous NIR catheter | | Drug‑resistant focal epilepsy | Rapid, localized suppression of hyper‑excitable networks | Intravenous loading dose + stereotactic NIR fiber placement | | Neuro‑prosthetic control | Enables bidirectional communication: a “push” signal to augment cortical output for prosthetic actuation | Systemic dosing + wearable NIR head‑gear for on‑demand activation | | Research tool for circuit mapping | Reversible, high‑temporal‑resolution control of specific neuronal populations | Systemic or intracerebral injection + flexible NIR illumination arrays |